Trials / Unknown
UnknownNCT03478540
Gut Microbiota and Immune Recovery
Impact of Gut Microbiota on the Immune Recovery in HIV-infection
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Shanghai Public Health Clinical Center · Other Government
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To explore whether gut microbiota would impact CD4 T cells recovery in HIV-infected patients on antiretroviral therapy (ART). We prospectively enroll patients initiate ART and collect their fecal at followup for one year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-Retroviral Agents | First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2019-05-30
- Completion
- 2019-05-30
- First posted
- 2018-03-27
- Last updated
- 2018-03-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03478540. Inclusion in this directory is not an endorsement.